Guinness Asset Management Ltd increased Aflac Inc (AFL) stake by 12.54% reported in 2017Q2 SEC filing. Guinness Asset Management Ltd acquired 19,320 shares as Aflac Inc (AFL)’s stock rose 3.90%. The Guinness Asset Management Ltd holds 173,440 shares with $13.47M value, up from 154,120 last quarter. Aflac Inc now has $34.91 billion valuation. The stock increased 0.36% or $0.32 during the last trading session, reaching $88.8. About 330,003 shares traded. Aflac Incorporated (NYSE:AFL) has risen 7.68% since December 12, 2016 and is uptrending. It has underperformed by 9.02% the S&P500.
Gofen & Glossberg Llc decreased Teva Pharmaceutical Ind Adr (TEVA) stake by 22.92% reported in 2017Q2 SEC filing. Gofen & Glossberg Llc sold 20,117 shares as Teva Pharmaceutical Ind Adr (TEVA)’s stock declined 15.11%. The Gofen & Glossberg Llc holds 67,651 shares with $2.25 million value, down from 87,768 last quarter. Teva Pharmaceutical Ind Adr now has $16.82 billion valuation. The stock increased 0.68% or $0.1121 during the last trading session, reaching $16.5521. About 8.56M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since December 12, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.
Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on February, 12. They expect $0.90 earnings per share, down 33.82% or $0.46 from last year’s $1.36 per share. TEVA’s profit will be $914.40 million for 4.60 P/E if the $0.90 EPS becomes a reality. After $0.95 actual earnings per share reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -5.26% negative EPS growth.
Gofen & Glossberg Llc increased Oaktree Capital Group Llc (NYSE:OAK) stake by 6,950 shares to 124,600 valued at $5.81M in 2017Q2. It also upped Becton Dickinson (NYSE:BDX) stake by 14,964 shares and now owns 26,944 shares. General Electric (NYSE:GE) was raised too.
Among 31 analysts covering Teva Pharma (NYSE:TEVA), 8 have Buy rating, 7 Sell and 16 Hold. Therefore 26% are positive. Teva Pharma had 114 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, July 14. Maxim Group maintained the shares of TEVA in report on Wednesday, November 16 with “Buy” rating. As per Thursday, October 5, the company rating was maintained by Morgan Stanley. Bank of America downgraded the stock to “Neutral” rating in Monday, November 7 report. The firm has “Neutral” rating given on Wednesday, August 16 by Citigroup. The firm has “Neutral” rating given on Tuesday, September 29 by Nomura. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Underperform” rating given on Thursday, August 24 by Credit Suisse. Piper Jaffray maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Friday, October 6 with “Hold” rating. The rating was reinitiated by Jefferies with “Buy” on Friday, October 30. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Buy” rating by Maxim Group on Wednesday, January 4.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.